Výsledky vyhledávání - "P F Fasching"

Pilot study: The LIPL-PLATELET study postprandial LIPid paneLs and PLATELET activity in coronary heart disease after treatment with PCSK9-inhibitors

Autor: E Pogran, A A Ahmed, A B Burger, C K Kaufmann, G R Rega-Kaun, P F Fasching, W H Huebl, K H Huber

Publikováno v: European Journal of Preventive Cardiology. 30

Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Sanofi AVentis Reports about a pleiotropic potential of pro-protein convertase subtilisin/kexin type 9 inhibitor are scarce. This hypothesis-generating study i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::adf4cbbcb3b6de537e621cf3ac0a542d
https://doi.org/10.1093/eurjpc/zwad125.318

Zobrazit plný text záznamu

Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin

Autor: Evangelos Giannitsis, M Kassem, C K Kaufmann, A S Spiel, M G Gschwantler, B Jaeger, P F Fasching, S E Equiluz-Bruck, G A Aicher, F V Vafai-Tabrizi, M F Freynhofer, Kurt Huber, A A Ahmed, J Wojta

Publikováno v: European Heart Journal

Background COVID-19 has been associated with a high prevalence of myocardial injury and increased cardiovascular morbidity. Copeptin, a marker of vasopressin release, has been previously established as a risk marker in both infectious and cardiovascu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a73ac38870ce650fc0a080d74a092f0
https://doi.org/10.1093/eurheartj/ehab724.3393

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání